Daiichi Sankyo and AstraZeneca’s Enhertu Plus Pertuzumab Approved in China for First-Line HER2+ Metastatic Breast Cancer
Aug 12, 2026
View online
Daiichi Sankyo and AstraZeneca’s Enhertu Plus Pertuzumab Approved in China for First-Line HER2+ Metastatic Breast Cancer
FDA is Announcing an Upcoming Meeting
Kevin Harrington: FDA Approval Marks a Major Breakthrough for RP1
Julie Gralow on Why Federal Funding Matters for the Future of Cancer Research
Germline BRCA1 Variants May Impair T Cell Function in Breast Cancer
10 Must-Read Posts In Radiotherapy This Week: August 2 -9
Five-Year CheckMate 648 Follow-Up: Nivolumab-Based Therapy in Advanced ESCC
Mammo 2026: Global Breast Cancer Virtual Congress
NCI Investigator-Initiated Early Phase Cancer Clinical Trials Grant 2026
NCI Sustained Cancer Informatics Technology Grant 2026
ESO-ESSO-ESTRO-ESP Multidisciplinary Course on Oncology for Medical Students
7th Global Cancer Summit (GCS 2026)
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
